The company buys in a PI3Kα and mTOR combo.
ApexOnco Front Page
Recent articles
Gilead opting against IDE397 is still good news for Ideaya.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
After a phase 3 push the livmoniplimab plan falters.
The company discontinues one of its two KRAS G12D degraders.
With a slashed valuation the newly listed biotech heads for phase 3.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
